Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antimalarial agents and lupus

D J Wallace1

  • 1Cedars-Sinai Medical Center, Los Angeles, California.

Rheumatic Diseases Clinics of North America
|February 1, 1994
PubMed
Summary
This summary is machine-generated.

Antimalarials are effective disease-modifying agents for lupus erythematosus management. They help induce remission, reduce dissemination risk, and improve various lupus symptoms without significant side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.

Annals of the rheumatic diseases·2021
Same author

Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities.

Annals of the rheumatic diseases·2020
Same author

Geographic access to buprenorphine prescribers for patients who use public transit.

Journal of substance abuse treatment·2020
Same author

Body image mediates the impact of pain on depressive symptoms in patients with systemic lupus erythematosus.

Lupus·2019
Same author

Psychometric validation of the Arthritis Helplessness Index in systemic lupus erythematosus.

Lupus·2018
Same author

Less than 7 hours of sleep per night is associated with transitioning to systemic lupus erythematosus.

Lupus·2018
Same journal

Bridging the Divide in Global Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence and Social Determinants of Health.

Rheumatic diseases clinics of North America·2026
Same journal

Updates in Ultrasound in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Health Systems Strengthening to Promote Access to Care for Rheumatic and Musculoskeletal Diseases Globally.

Rheumatic diseases clinics of North America·2026
See all related articles

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Lupus erythematosus is a complex autoimmune disease.
  • Current treatments have limitations and potential side effects.
  • Antimalarials are under-utilized in lupus management.

Purpose of the Study:

  • To review the role of antimalarials in lupus erythematosus.
  • To highlight the disease-modifying properties of antimalarials.
  • To discuss the potential of antimalarials in combination therapy.

Main Methods:

  • Literature review of antimalarial use in lupus.
  • Analysis of clinical trial data and observational studies.
  • Synthesis of evidence on efficacy and safety.

Related Experiment Videos

Main Results:

  • Antimalarials promote remission in non-organ-threatening lupus.
  • They reduce the risk of lupus dissemination.
  • Beneficial effects observed in cutaneous, joint, serositis, fatigue, and cognitive symptoms.

Conclusions:

  • Antimalarials are valuable disease-modifying agents for lupus.
  • They offer a favorable safety profile, not affecting bone marrow or causing infections.
  • Potential for combination therapy with other lupus medications exists.